文献速递临床试验与 GCP

替奈普酶用于缺血性卒中后4.5至24小时非大血管闭塞:OPTION随机临床试验

Tenecteplase for Acute Non-Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke: The OPTION Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

这项在中国48家中心开展的随机、开放标签、盲法终点试验纳入566例非大血管闭塞且灌注影像提示存在可挽救脑组织的缺血性卒中患者,于症状出现后4.5至24小时随机给予静脉替奈普酶(0.25 mg/kg,最大25 mg)或标准药物治疗。替奈普酶组90天极佳功能结局(改良Rankin量表评分0或1分)比例高于对照组,但症状性颅内出血发生率更高,90天死亡率两组无显著差异。

要点

  • 替奈普酶组90天极佳功能结局43.6%,对照组34.2%(风险比1.28,95%CI 1.04-1.57;P=0.02)。
  • 替奈普酶组症状性颅内出血2.8%,对照组0%(风险差2.85%,95%CI 1.16%-5.54%;P=0.004)。
  • 90天死亡率替奈普酶组5.0%,对照组3.2%(风险比1.57,95%CI 0.69-3.57;P=0.28),无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The efficacy and safety of intravenous tenecteplase in non-large vessel occlusion acute ischemic stroke beyond 4.5 hours after symptom onset remain uncertain. OBJECTIVE: To assess the efficacy and safety of intravenous tenecteplase administered 4.5 to 24 hours after stroke onset in patients with non-large vessel occlusion and salvageable brain tissue. DESIGN, SETTING, AND PARTICIPANTS: This randomized, open-label, blinded end-point clinical trial was conducted at 48 centers in China. A total of 566 patients with non-large vessel occlusion stroke and evidence of potentially salvageable tissue determined on perfusion imaging presenting within 4.5 to 24 hours of the time last seen well were recruited between June 2, 2023, and August 4, 2025 (final follow-up, October 28, 2025). INTERVENTIONS: Patients were randomly assigned 1:1 using a minimization algorithm to receive intravenous tenecteplase (0.25 mg/kg; maximum dose, 25 mg; n = 282) or standard medical treatment (n = 284). MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was an excellent functional outcome, defined as a score of 0 or 1 on the modified Rankin Scale at 90 days. Safety outcomes included symptomatic intracranial hemorrhage within 36 hours and mortality within 90 days. RESULTS: Among the 570 patients randomized, 566 were included in the primary analysis (median age, 68 [IQR, 59-75] years; 196 female [34.6%]). An excellent functional outcome was observed in 123 of 282 patients (43.6%) in the tenecteplase group and 97 of 284 (34.2%) in the control group (risk ratio, 1.28 [95% CI, 1.04-1.57]; P = .02). The incidence of symptomatic intracranial hemorrhage at 2.8% was higher with tenecteplase than with standard medical treatment at 0% (risk difference, 2.85% [95% CI, 1.16%-5.54%]; P = .004), and the mortality at 90 days was 5.0% and 3.2%, respectively (risk ratio, 1.57 [95% CI, 0.69-3.57]; P = .28). CONCLUSIONS AND RELEVANCE: Among patients with non-large vessel occlusion acute ischemic stroke and salvageable brain tissue, intravenous tenecteplase administered 4.5 to 24 hours after onset resulted in a greater likelihood of an excellent functional outcome at 90 days than standard care but had an increased risk of symptomatic intracranial hemorrhage. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05752916.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Ma G, Mo R, Zuo Y, et al. Tenecteplase for Acute Non-Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke: The OPTION Randomized Clinical Trial. JAMA. 2026. PMID: 41642827. doi:10.1001/jama.2026.0210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。